Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CH1242303498
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01BJ1BHZ3
OCS
Oculis Holding AG
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology
NAME
Oculis Holding AG
ISIN
CH1242303498
TICKER
OCS
MIC
XNAS
REUTERS
OCS.OQ
BLOOMBERG
OCS US
Mon, 24.08.2026       Oculis Holding
CH1242303498

The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division. The PIONEER program marks a key step toward potential f...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.08.2026       Oculis Holding
CH1242303498

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announces that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.08.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Oculis Holding
CH1242303498

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a private translation...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Oculis Holding
CH1242303498

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a private translational...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.08.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced results for the second quarter ended June 30, 2026, and provided an ov...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.08.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced results for the second quarter ended June 30, 2026, and provided an o...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced positive U.S. Food and Drug Administration (FDA) p...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced positive U.S. Food and Drug Administration (FDA) pr...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.07.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 02.07.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.07.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the Piper Sandler...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.06.2026       Oculis Holding
CH1242303498

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investiga...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.06.2026       Oculis Holding
CH1242303498

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investiga...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Executive Committee....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Oculis Holding
CH1242303498

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or "the Company") (NASDAQ: OCS) for violations of the securities laws. The in...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Oculis Holding
CH1242303498

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investig...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking p...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the S...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.06.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, June 10, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 09.06.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Executive Committee and Board of Directors....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that the first patient has been randomized in the PREDICT-1 (Persona...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.06.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, June 9, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that the first patient has been randomized in the PREDICT-1 (Personalized dRy Eye Diseas...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.06.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.06.2026       Oculis Holding
CH1242303498

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Con...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.06.2026       Oculis Holding
CH1242303498

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or "the Company") (NASDAQ: OCS) for violations of the securities laws. The inv...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.06.2026       Oculis Holding
CH1242303498

Oculis Holding AG shares collapsed approximately 23% after Phase 3 DIAMOND trials for lead product OCS-01 failed to meet the primary endpoint in diabetic macular edema.NEW YORK, June 8, 2026 /PRNewswire/ -- Investors in Oculis Holding AG (NASDAQ: OCS) lost approximately 23% of their share value in a single session after the company disclosed that...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.06.2026       Oculis Holding
CH1242303498

New York, New York--(Newsfile Corp. - June 8, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Oculis Holding AG ("Oculis Holding AG") (NASDAQ: OCS) concerning potential violations of the federal securities laws.Multiple SEC filings made prior to the stock collapse continued to present the OCS-01 DME progr...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Oculis Holding
CH1242303498

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ: OCS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.06.2026       Oculis Holding
CH1242303498

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.06.2026       Oculis Holding
CH1242303498

Shareholders of Oculis Holding AG (NASDAQ: OCS) lost nearly $7 per share, more than 23%, in a single trading session when the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint -- mean change in best-corrected visual acuity at week 52 -- in diabetic macular edema. Oculis simultaneously...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       Oculis Holding
CH1242303498

Oculis Holding AG claimed its "most important" drug, OSC-01, was biologically approved months before revealing the Phase 3 Diamond studies concerning the drug had failed to achieve their primary endpoints.NEW YORK, June 2, 2026 /PRNewswire/ -- Investors in Oculis Holding AG (NASDAQ: OCS) lost approximately 23.4% of their holdings in a single sessi...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2026       Oculis Holding
CH1242303498

Oculis Holding AG SEC filings continued to describe the OCS-01 DME program as on track for FDA submission after Phase 3 DIAMOND trials had already failed -- shares fell over 23%NEW YORK, June 1, 2026 /PRNewswire/ -- Investors in Oculis Holding AG (NASDAQ: OCS) lost approximately 23.4% of their holdings in a single session after the Company disclos...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2026       Oculis Holding
CH1242303498

New York, New York--(Newsfile Corp. - June 1, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Oculis Holding AG ("Oculis Holding AG") (NASDAQ: OCS) concerning potential violations of the federal securities laws.Multiple SEC filings made prior to the stock collapse continued to present the OCS-01 DME progr...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Oculis Holding
CH1242303498

Zug, Sviss, May 29, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun við meðferð á augn- og augntaugasjúkdómum í því skyni að mæta verulegum óuppfylltum læknisfræðilegum tilkynnti í dag um helstu niðurstöður úr fasa 3 DIAMOND-1 og DIAMOND-2 rannsóknunum á OCS-01 au...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Oculis Holding
CH1242303498

Instrument ID [16002404] (CR5 - CH1242303498) suspended...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Conference call today at 4:30 pm ET...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 15.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive awards granted to directors of the Company, and the one-time equity incentive award granted to a new director upon his election to the board of direc...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m. CEST, including the election of Gregory D. Perry to its Board of Dir...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m. CEST, including the election of Gregory D. Perry to its Board of Dir...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the first quarter ended March 31, 2026, and provided an ove...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug A...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) un...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announces that the latest findings of the DME AWARE Delphi study were presented a...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announces that the latest findings of the DME AWARE Delphi study were presented...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it will be highlighting the transformative potential of its late-...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.05.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it will be highlighting the transformative potential of its late-s...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink